ACAD
30.46
-0.59
-1.90%
AEMD
0.25
0.00
-1.19%
APRI
1.39
-0.04
-2.80%
ARNA
4.32
-0.2
-4.32%
ATEC
1.29
-0.02
-1.53%
CFN
59.33
-0.28
-0.46%
CNAT
5.82
-0.14
-2.35%
CRXM
0.21
0.00
-1.38%
CYTX
0.48
+0.01
+1.89%
DXCM
59.81
-1.19
-1.95%
GNMK
12.89
-0.42
-3.16%
HALO
14.29
-0.3
-2.06%
ILMN
195.68
-4.32
-2.16%
INNV
0.22
+0.01
+4.19%
INO
8.33
-0.17
-2.00%
ISCO
0.06
0.00
0.00%
ISIS
68.56
-1.3
-1.86%
LGND
56.43
-0.6
-1.05%
LPTN
2.76
-0.09
-3.16%
MBVX
1.04
-0.01
-0.95%
MEIP
3.98
+0.12
+3.11%
MNOV
3.79
+0.02
+0.53%
MRTX
20.67
-0.62
-2.91%
MSTX
0.45
+0.01
+3.37%
NBIX
33.71
-0.64
-1.86%
NUVA
46.31
-0.99
-2.09%
ONCS
0.36
-0.01
-2.74%
ONVO
6.41
-0.28
-4.19%
OREX
5.26
-0.1
-1.78%
OTIC
29.25
-2.32
-7.35%
QDEL
23.53
-0.94
-3.84%
RCPT
110.06
-2.65
-2.35%
RGLS
19.15
+0.57
+3.04%
RMD
62.52
-0.51
-0.81%
SCIE
0.01
0.00
-2.65%
SPHS
0.48
+0.01
+1.34%
SRNE
10.1
-0.68
-6.31%
TROV
6.48
+0.65
+11.17%
VICL
1.03
-0.01
-0.96%
VOLC
17.96
0.00
0.00%
ZGNX
1.36
-0.01
-0.74%
Home » Archive by Category

News

San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

Ansun Biopharma, Inc. Resolves Government Investigation, Continues Development Of Late Phase Investigational Anti-Viral Therapies

January 8, 2015 – 11:41 am | Edit Post
Ansun Biopharma, Inc. Resolves Government Investigation, Continues Development Of Late Phase Investigational Anti-Viral Therapies

SAN DIEGO, Jan. 8, 2015 /PRNewswire/ — Ansun Biopharma, Inc., a San Diego-based biotech company, is pleased to announce that it has entered into an agreement with the United States Attorneys Office resolving an investigation of Ansun. The Company has cooperated with the United States Attorneys Office in San Diego to uncover misconduct by its former CEO and CFO that occurred over 4 years ago. Both individuals were removed from their positions with the Company in 2011 shortly after the Company became aware of the investigation.  The Company’s former CEO has since pled guilty to a misdemeanor and its former CFO entered into an agreement with the government, which resulted in a dismissal of any charges against her.

In October of 2011, Ansun replaced its then Board of Directors with a new slate of Board members and appointed new management, including Dr. Ronald Moss, who has been Ansun’s CEO since then.  Ansun has made significant progress in the development of therapies for diseases caused by common viruses such as influenza and parainfluenza. “We continue to work with leaders in the medical community to develop therapies for unmet medical need. Our investigational drugs for influenza and parainfluenza are in late stage clinical development.  It is very clear based on the current influenza epidemic that more therapies are urgently needed and Ansun is committed to developing these therapies for patients,” said Dr. Moss.  In September of 2012, Ansun received a contract from the Biomedical Advanced Research and Development Authority in the amount of $26,500,000 to continue development of Fludase®, its lead compound for treatment of the flu.  Ansun’s pipeline consists of Fludase®, and Paradase™ both of which are in human clinical trials.

Fludase®, a broad spectrum investigational antiviral biologic has completed phase 2 studies and is ready for the last stage of clinical development.  In studies conducted with the CDC, Fludase has shown broad activities  against many strains of influenza including the circulating strains of the current influenza epidemic and the H5N1 strain of bird flu, which has a significantly high mortality rate in infected humans.

Its experimental biologic Paradase is also in human clinical trials.  “With Paradase, we are currently enrolling a phase 2 study in cancer and transplant patients infected with a deadly virus called parainfluenza,” stated Dr. Moss.  Infection with this virus in these patients with suppressed immune systems is high and there are no current treatments available.  “In addition to enrolling the phase 2 study, Ansun has provided Paradase for parainfluenza to over 70 dying transplant and leukemic patients under emergency use requests from physicians across the United States,” explained Dr. Moss. 

“We are very pleased that the investigation has been resolved.  It never changed our focus, but now with the investigation behind us, we feel a renewed energy to develop novel and effective tools to provide the U.S. government and the public potential therapies for the defense against viruses that affect public health and welfare,” said Dr. Moss.

For more information, please refer to Ansun’s website at www.ansunbiopharma.com or contact:
Mark Geragos
Geragos & Geragos, APC
(213) 625-3900
mark@geragos.com

 

SOURCE Ansun Biopharma, Inc.

BioPharmX Corporation To Present At OneMed Forum SF 2015 Conference

January 8, 2015 – 8:00 am | Edit Post
BioPharmX Corporation To Present At OneMed Forum SF 2015 Conference

MENLO PARK, Calif., Jan. 8, 2015 /PRNewswire/ — BioPharmX Corporation (OTCQB: BPMX), a biotechnology company focused on the development of novel drug delivery products to address unmet needs in large, well-defined and underserved markets, today announced that Jim Pekarsky, chief executive officer and co-founder of BioPharmX, will present at the OneMed Forum SF 2015 Conference on Monday, January 12 at 3:00 p.m. PST at the Marriott Marquis in San Francisco. 

Mr. Pekarsky will provide an overview of BioPharmX’s business strategy as it pursues bringing novel products to market, including the company’s recent commercial launch of VioletTM iodine, a new, once-daily pill for relief of premenstrual breast discomfort.  Violet iodine is currently available at Walgreen Co.’s drugstore.com™ web store and BioPharmX anticipates rolling out Violet iodine to other large retail chains.

A live and archived webcast of the presentation will be available on the Investors page of the BioPharmX website at http://biopharmx.investorroom.com/.

About BioPharmX Corporation

BioPharmX Corporation (OTCQB: BPMX) is a Silicon Valley-based biotechnology company, which seeks to provide innovative products through unique, proprietary platform technologies for prescription, over-the-counter (“OTC”), and supplement applications in the fast-growing health and wellness markets, including women’s health, dermatology, and otolaryngology (ears, nose & throat).  To learn more about BioPharmX, visit www.BioPharmX.com.

Forward-Looking Statements

Statements in this news release relating to the business of BioPharmX, which are not historical facts, are “forward-looking statements.”  These forward-looking statements may be identified by words such as “expect,” “anticipate,” “believe,” or similar expressions that are intended to identify such forward-looking statements.  All forward-looking statements are expressly qualified in their entirety by this cautionary statement and the risks and other factors detailed in the company’s filings with the Securities and Exchange Commission (SEC). These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risk that the commercial launch of Violet iodine is unsuccessful and that the company is unable to offer Violet iodine through other retail chains. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements.  The forward-looking statements included in this news release are made only as of the date hereof and the company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.

BioPharmX and Violet are pending trademarks of BioPharmX Inc.  All other brand and product names are trademarks or registered trademarks of their respective holders.

 

SOURCE BioPharmX

BioPharmX Corporation To Present At OneMed Forum SF 2015 Conference

January 8, 2015 – 8:00 am | Edit Post
BioPharmX Corporation To Present At OneMed Forum SF 2015 Conference

MENLO PARK, Calif., Jan. 8, 2015 /PRNewswire/ — BioPharmX Corporation (OTCQB: BPMX), a biotechnology company focused on the development of novel drug delivery products to address unmet needs in large, well-defined and underserved markets, today announced that Jim Pekarsky, chief executive officer and co-founder of BioPharmX, will present at the OneMed Forum SF 2015 Conference on Monday, January 12 at 3:00 p.m. PST at the Marriott Marquis in San Francisco. 

Mr. Pekarsky will provide an overview of BioPharmX’s business strategy as it pursues bringing novel products to market, including the company’s recent commercial launch of VioletTM iodine, a new, once-daily pill for relief of premenstrual breast discomfort.  Violet iodine is currently available at Walgreen Co.’s drugstore.com™ web store and BioPharmX anticipates rolling out Violet iodine to other large retail chains.

A live and archived webcast of the presentation will be available on the Investors page of the BioPharmX website at http://biopharmx.investorroom.com/.

About BioPharmX Corporation

BioPharmX Corporation (OTCQB: BPMX) is a Silicon Valley-based biotechnology company, which seeks to provide innovative products through unique, proprietary platform technologies for prescription, over-the-counter (“OTC”), and supplement applications in the fast-growing health and wellness markets, including women’s health, dermatology, and otolaryngology (ears, nose & throat).  To learn more about BioPharmX, visit www.BioPharmX.com.

Forward-Looking Statements

Statements in this news release relating to the business of BioPharmX, which are not historical facts, are “forward-looking statements.”  These forward-looking statements may be identified by words such as “expect,” “anticipate,” “believe,” or similar expressions that are intended to identify such forward-looking statements.  All forward-looking statements are expressly qualified in their entirety by this cautionary statement and the risks and other factors detailed in the company’s filings with the Securities and Exchange Commission (SEC). These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risk that the commercial launch of Violet iodine is unsuccessful and that the company is unable to offer Violet iodine through other retail chains. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements.  The forward-looking statements included in this news release are made only as of the date hereof and the company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.

BioPharmX and Violet are pending trademarks of BioPharmX Inc.  All other brand and product names are trademarks or registered trademarks of their respective holders.

 

SOURCE BioPharmX

Adah Almutairi Breaks Down Barriers at Berlin’s “Falling Walls” Conference

January 8, 2015 – 7:00 am | Edit Post
Adah Almutairi Breaks Down Barriers at Berlin’s “Falling Walls” Conference

Adah Almutairi is a polymer chemist. But if you give her a blank look at the mere mention of “polymers,” she might quickly change that to say she’s a “construction worker… on the nano scale” or a “plastics chemist,” the term she used to introduce herself at the recent Falling Walls conference in Berlin.

Squidtoons: Sparking Scientific Curiosity through Comics

January 8, 2015 – 7:00 am | Edit Post
Squidtoons: Sparking Scientific Curiosity through Comics

As a young boy growing up in Hong Kong, Tsz Fung Kwan looked forward to reading the famous Jim Davis comic strip Garfield in the Sunday paper. Something about the iconic orange, lasagna-loving cat struck a chord with Kwan, and, at the age of 7, when his family immigrated to the United states in search of a better life, he paid homage to his comic hero by choosing “Garfield” as his new American name.

Squidtoons: Sparking Scientific Curiosity through Comics

January 8, 2015 – 7:00 am | Edit Post
Squidtoons: Sparking Scientific Curiosity through Comics

As a young boy growing up in Hong Kong, Tsz Fung Kwan looked forward to reading the famous Jim Davis comic strip Garfield in the Sunday paper. Something about the iconic orange, lasagna-loving cat struck a chord with Kwan, and, at the age of 7, when his family immigrated to the United states in search of a better life, he paid homage to his comic hero by choosing “Garfield” as his new American name.

Squidtoons: Sparking Scientific Curiosity through Comics

January 8, 2015 – 7:00 am | Edit Post
Squidtoons: Sparking Scientific Curiosity through Comics

As a young boy growing up in Hong Kong, Tsz Fung Kwan looked forward to reading the famous Jim Davis comic strip Garfield in the Sunday paper. Something about the iconic orange, lasagna-loving cat struck a chord with Kwan, and, at the age of 7, when his family immigrated to the United states in search of a better life, he paid homage to his comic hero by choosing “Garfield” as his new American name.

Squidtoons: Sparking Scientific Curiosity through Comics

January 8, 2015 – 7:00 am | Edit Post
Squidtoons: Sparking Scientific Curiosity through Comics

As a young boy growing up in Hong Kong, Tsz Fung Kwan looked forward to reading the famous Jim Davis comic strip Garfield in the Sunday paper. Something about the iconic orange, lasagna-loving cat struck a chord with Kwan, and, at the age of 7, when his family immigrated to the United states in search of a better life, he paid homage to his comic hero by choosing “Garfield” as his new American name.

ViaCyte Receives Clearance from Health Canada for Diabetes Clinical Trial

January 8, 2015 – 7:00 am | Edit Post
ViaCyte Receives Clearance from Health Canada for Diabetes Clinical Trial

SAN DIEGO, Jan. 8, 2015 /PRNewswire/ — ViaCyte, Inc., a privately-held regenerative medicine company with the first stem cell-derived islet replacement therapy for the treatment of diabetes in clinical trials, has received a No Objection Letter from Health Canada providing clearance to proceed with sites in Canada for the Company’s Phase 1/2 clinical trial of its VC-01TM product candidate.  The VC-01 product candidate is currently being evaluated in patients with type 1 diabetes who have minimal to no insulin-producing beta cell function.  The location and enrollment start date of the first Canadian clinical trial site have not yet been disclosed. 

“The first cohort of patients in this two-cohort dose escalation study of the VC-01 product candidate is currently being assessed at a single site in the United States.  Should the product candidate proceed to the second cohort, we intend to expand the trial to multiple sites,” said Paul Laikind, PhD, President and CEO of ViaCyte.  “Health Canada’s approval represents further validation of the trial and allows us to expand internationally to one or more sites in Canada.”

The Investigational New Drug application for the Phase 1/2 trial, called STEP ONE, or Safety, Tolerability, and Efficacy of VC-01 Combination Product in Type 1, was allowed by the US Food and Drug Administration in August 2014.  The STEP ONE trial was launched in September 2014 at UC San Diego Health System, with the support of the UC San Diego Sanford Stem Cell Clinical Center and under the direction of Principal Investigator Robert Henry, MD.  The first implant was performed in October 2014. 

In addition to determining the safety of the product candidate in these patients, STEP ONE is designed to evaluate the effectiveness of the VC-01 product candidate in replacing the lost endocrine function that is central to the disease.  In an open-label, dose-escalating format, ViaCyte expects to enroll approximately 40 patients in the study at multiple clinical sites. 

About ViaCyte

ViaCyte is a privately-held, clinical-stage regenerative medicine company focused on developing a novel cell therapy for the treatment of diabetes.  ViaCyte is conducting a Phase 1/2 clinical trial, called STEP ONE, of the Company’s lead product candidate VC-01 in patients with type 1 diabetes who have minimal to no insulin-producing beta cell function.  The VC-01 combination product is based on the production of pancreatic progenitor cells (PEC-01™ cells), which are implanted in a durable and retrievable encapsulation device, known as the Encaptra® drug delivery system.  Once implanted and matured, these cells are designed to secrete insulin and other regulatory factors in response to blood glucose levels.  The VC-01 combination product is being developed as a potential long-term diabetes treatment without immune suppression and without risk of hypoglycemia or other diabetes-related complications.

ViaCyte is headquartered in San Diego, California with additional operations in Athens, Georgia.  The Company is funded in part by the California Institute for Regenerative Medicine and JDRF.  For more information, please visit www.viacyte.com.

Logo – http://photos.prnewswire.com/prnh/20121026/LA00871LOGO-a

 

SOURCE ViaCyte, Inc.

Orexigen Therapeutics to Present at the J.P. Morgan 2015 Healthcare Conference

January 8, 2015 – 7:00 am | Edit Post
Orexigen Therapeutics to Present at the J.P. Morgan 2015 Healthcare Conference

SAN DIEGO, Jan. 8, 2015 /PRNewswire/ — Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the J.P. Morgan 2015 Healthcare Conference in San Francisco. The presentation is scheduled for Tuesday, January 13, at 8:00 a.m. Pacific Time. To listen to the live webcast or a replay of the presentation, please visit the Investors section of the Company’s Web site at www.orexigen.com. A replay will be available for 14 days after the event.

Investor Contact
McDavid Stilwell
VP, Corporate Communications and Business Development
(858) 875-8629

Media Contact
David Walsey
BrewLife, Inc.
(858) 617-0772

 

SOURCE Orexigen Therapeutics, Inc.